BIVI ▲ +7.4% - BioVie Inc.
$BIVI - BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie shares rose 7.4% after the company announced it has completed the treatment phase of its ADDRESS-LC trial evaluating bezisterim for neurological symptoms in long COVID patients. The completion of this trial phase represents meaningful progress in the company's clinical development program, which likely prompted the positive market reaction. The next step would typically be data analysis and potential regulatory discussions based on the trial results.
31-AUG-2026 08:01 AM ET
Share this post
More filings for $BIVI
BIVI ▼ -2.3% - BioVie Inc.Nov 10, 2026BIVI ▲ +1.5% - BioVie Inc.Nov 9, 2026BIVI - BioVie Inc. - SEC Filing Update (06-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 6, 2026BIVI ▼ -14.0% - BioVie Inc.Nov 4, 2026BIVI ▼ -2.8% - BioVie Inc.Nov 2, 2026BIVI ▼ -3.2% - BioVie Inc.Oct 26, 2026
View full $BIVI filing history →💬 Comments
Loading comments…
Leave a comment
